Literature DB >> 3106409

Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains.

E D Anastassiou, A C Mintzas, C Kounavis, G Dimitracopoulos.   

Abstract

The slime material from a revertant nonmucoid variant, derived by serial passage of a heavily mucoid Pseudomonas aeruginosa strain isolated from a patient with bacteremia, was found to contain 16% uronic acids, 48.5% carbohydrates, 11% protein, and 2% lipids. Chromatographic analysis by ion exchange chromatography revealed that this extracellular material consisted of three fractions, one uronic acid fraction with properties similar to those of the alginate fraction of the parental strain and two other fractions consisting of neutral sugars and proteins in approximately a 5:1 ratio. In addition, the slime material from six other clinical macroscopic nonmucoid P. aeruginosa strains was found to contain alginate. These results demonstrate that alginate production in various amounts is a property shared by all P. aeruginosa strains.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106409      PMCID: PMC266054          DOI: 10.1128/jcm.25.4.656-659.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  STUDIES ON THE GRAM-NEGATIVE CELL WALL. I. EVIDENCE FOR THE ROLE OF 2-KETO- 3-DEOXYOCTONATE IN THE LIPOPOLYSACCHARIDE OF SALMONELLA TYPHIMURIUM.

Authors:  M J OSBORN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-09       Impact factor: 11.205

2.  The distribution of 2-keto-3-deoxy-octonic acid in bacterial walls.

Authors:  D C Ellwood
Journal:  J Gen Microbiol       Date:  1970-03

3.  Mucoid Pseudomonas aeruginosa in patients with chronic illnesses.

Authors:  R G Doggett; G M Harrison; R E Carter
Journal:  Lancet       Date:  1971-01-30       Impact factor: 79.321

4.  The slime of Pseudomonas aeruginosa: biological characterization and possible role in experimental infection.

Authors:  J W Sensakovic; P F Bartell
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

5.  Incidence of mucoid Pseudomonas aeruginosa from clinical sources.

Authors:  R G Doggett
Journal:  Appl Microbiol       Date:  1969-11

6.  Composition of Pseudomonas aeruginosa slime.

Authors:  M R Brown; J H Foster; J R Clamp
Journal:  Biochem J       Date:  1969-05       Impact factor: 3.857

7.  Epidemiological markers for Pseudomonas aeruginosa. 6. Relationship between concomitant non-mucoid and mucoid strains from the respiratory tract in cystic fibrosis.

Authors:  T Bergan; N Hoiby
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1975-12

8.  Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate.

Authors:  D E Ohman; A M Chakrabarty
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

9.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors:  G B Pier; W J Matthews; D D Eardley
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

10.  Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis.

Authors:  J Lam; R Chan; K Lam; J W Costerton
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

View more
  20 in total

1.  AlgR, a response regulator controlling mucoidy in Pseudomonas aeruginosa, binds to the FUS sites of the algD promoter located unusually far upstream from the mRNA start site.

Authors:  C D Mohr; N S Hibler; V Deretic
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

2.  Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model.

Authors:  Alessandra Bragonzi; Dieter Worlitzsch; Gerald B Pier; Petra Timpert; Martina Ulrich; Morten Hentzer; Jens Bo Andersen; Michael Givskov; Massimo Conese; Gerd Doring
Journal:  J Infect Dis       Date:  2005-06-24       Impact factor: 5.226

3.  The algT gene of Pseudomonas syringae pv. glycinea and new insights into the transcriptional organization of the algT-muc gene cluster.

Authors:  Alexander Schenk; Michael Berger; Lisa M Keith; Carol L Bender; Georgi Muskhelishvili; Matthias S Ullrich
Journal:  J Bacteriol       Date:  2006-09-29       Impact factor: 3.490

4.  Virulence determinants in Pseudomonas aeruginosa strains from urinary tract infections.

Authors:  P Visca; F Chiarini; A Mansi; C Vetriani; L Serino; N Orsi
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

5.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

6.  Phase variation of slime production in Staphylococcus aureus: implications in colonization and virulence.

Authors:  R Baselga; I Albizu; M De La Cruz; E Del Cacho; M Barberan; B Amorena
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

7.  Multiple promoters and induction by heat shock of the gene encoding the alternative sigma factor AlgU (sigma E) which controls mucoidy in cystic fibrosis isolates of Pseudomonas aeruginosa.

Authors:  M J Schurr; H Yu; J C Boucher; N S Hibler; V Deretic
Journal:  J Bacteriol       Date:  1995-10       Impact factor: 3.490

Review 8.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

9.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

10.  Pseudomonas aeruginosa slime glycolipoprotein is a potent stimulant of tumor necrosis factor alpha gene expression and activation of transcription activators nuclear factor kappa B and activator protein 1 in human monocytes.

Authors:  George Lagoumintzis; Myrto Christofidou; George Dimitracopoulos; Fotini Paliogianni
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.